

26 October 2011

The Manager  
Company Announcements Office  
ASX Limited  
20 Bridge St  
SYDNEY NSW 2000

Dear Sir,

**BOARD AND MANAGEMENT CHANGE**

CBio Limited (ASX: CBZ) wishes to announce that Mr James Greig has resigned as a director of the Company. Mr Greig joined CBio in 2006 as Financial Controller and was appointed Chief Financial Officer later that year. In January 2011, Mr Greig was appointed to the Board as Executive Finance Director, a position he held until October 12 when he resigned from his executive position.

Mr Ben Graham has resigned as Chief Financial Officer of the company. Mr Graham joined CBio in 2005 as a Financial Accountant and was appointed Company Secretary in 2007. Mr Graham will remain as Company Secretary, although as previously advised to the market he will step down from this role in the near future.

“ It’s a sad day for CBio to be losing James and Ben, both of whom have been with the company for a number of years” said CBio Chairman Mr Stephen Jones.

“They have both worked tirelessly for CBio in that time and I wish them both the very best in their future endeavours”

For and on behalf of the Board of CBio Limited.



**BEN GRAHAM**  
Company Secretary

**About CBio Limited**

CBio is an Australian ASX listed company established in 2000. CBio’s lead product XToll® is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA). Global sales of RA therapies exceeded US\$17 billion in 2008. Novo Nordisk A/S, a top 20 global pharmaceutical company and world-leader in diabetes care, has an exclusive option to enter into a licence agreement for the intellectual property rights relating to XToll®. XToll® has been trialled in over 330

patients with no pattern of treatment-emergent serious adverse effects. The company's largest clinical trial to date completed in Q2 2011. CBio's Board includes internationally experienced drug developers including Dr Goran Ando, Vice-Chairman Novo Nordisk A/S (formerly president of R&D at Pharmacia/Pfizer and R&D director of Glaxo Group, UK); Dr Thomas Lönngren (former Executive Director of the European Medicines Agency), Dr Terje Kalland, Chief Scientific Officer of Karolinska Development (formerly Senior-Vice President Biopharmaceuticals Research Unit- Novo Nordisk and Head of Oncology Research, Pharmacia); Dr Peter Corr, Founder and co-General Partner of Celtic Therapeutics (formerly Senior Vice-President for Science and Technology at Pfizer and Chairman of the Board of Governors, New York Academy of Sciences); and Professor John Funder, AO, Professor of Medicine at Monash University, Senior Fellow at Prince Henry's Institute of Medical Research (formerly Director of the Baker Institute, 1990-2001).

#### **About Rheumatoid Arthritis**

Rheumatoid Arthritis is a chronic autoimmune disease, mainly characterised by inflammation of the lining of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. The effects of RA are systemic, which means it can affect other organs in the body, and cardiovascular dysfunction in addition to RA is common. RA symptoms can make even the simplest activities – such as opening a jar or taking a walk – difficult to manage. RA has a worldwide distribution with a prevalence of 1 to 2% – which currently equates to approximately 100 million people. Prevalence increases with age, approaching 5% in women over age 55. RA is two to three times more common in women than in men and generally occurs between the ages of 40 and 60, but it can also affect young children and older adults. Currently, there is no cure.

#### **COMPANY & INVESTOR RELATIONS**

Ben Graham  
Company Secretary  
CBio Limited  
T: +61 7 3841 4844  
ben.graham@cbio.com.au

#### **MEDIA LIAISON**

Melanie Farris  
Manager, Corporate Projects  
CBio Limited  
T: +61 449 148 448  
melanie.farris@cbio.com.au